Medpace Holdings Inc ( (MEDP) ) has released its Q2 earnings. Here is a breakdown of the information Medpace Holdings Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medpace Holdings, Inc. is a global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Headquartered in Cincinnati, Ohio, the company is known for its scientifically-driven approach and expertise across various therapeutic areas.
In its second quarter of 2025 earnings report, Medpace Holdings, Inc. announced a significant increase in revenue and net new business awards, reflecting robust growth and operational efficiency. The company’s revenue for the quarter reached $603.3 million, marking a 14.2% increase compared to the same period last year.
Key financial metrics from the report include a 12.6% rise in net new business awards to $620.5 million, resulting in a net book-to-bill ratio of 1.03x. The company’s GAAP net income for the quarter was $90.3 million, or $3.10 per diluted share, slightly up from the previous year’s $88.4 million. Additionally, EBITDA increased by 16.2% to $130.5 million, highlighting strong operational performance.
Medpace’s financial guidance for 2025 projects revenue growth between 14.7% and 19.5%, with expected GAAP net income ranging from $405.0 million to $428.0 million. The company anticipates full-year EBITDA to be between $515.0 million and $545.0 million, indicating continued confidence in its growth trajectory.
Looking ahead, Medpace Holdings remains focused on leveraging its scientific expertise and disciplined operating approach to drive further growth and innovation in the clinical research sector, while maintaining a strong financial position.